Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as [18F]MK-0947
MK-0947 · 1 trial · 3 indications
Incidence of adverse events (AEs) following administration
Radiation absorbed dose estimates following administration derived from PET imaging and dosimetry calculations.
| Arm | Type | Description |
|---|---|---|
| Part 1 - Brain Imaging | EXPERIMENTAL | Participants receive \[18F\]MK-0947 for PET imaging of the brain. |
| Part 2 - Dosimetry | EXPERIMENTAL | Healthy participants receive \[18F\]MK-0947 for whole-body dosimetry. |
| Name | Type | Description |
|---|---|---|
| [18F]MK-0947 | DRUG | PET radiopharmaceutical selective for α-synuclein, administered IV at doses up to 10 mCi. |
Inclusion Criteria: * Signed informed consent prior to any study procedures * Women of childbearing potential: abstinent or use 2 contraception methods (one barrier) during study and 90 days post last injection * Men: use 2 contraception methods and refrain from sperm donation during study and 90 d...
MK-0947 is an investigational small molecule being studied for use in Parkinson's Disease (PD). It is a positron emission tomography (PET) imaging agent, also known as [18F]MK-0947, designed to evaluate brain alpha-synuclein deposition. It is currently in Phase 1 clinical development and is not yet approved.
MK-0947 targets alpha-synuclein, a protein that forms clumps in the brains of people with Parkinson's Disease. As a PET imaging agent, it is designed to bind to alpha-synuclein deposits so they can be visualized on a brain scan, potentially aiding in the diagnosis and monitoring of Parkinson's Disease.
MK-0947 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company is conducting a Phase 1 clinical trial of this investigational PET imaging agent for Parkinson's Disease.
MK-0947 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing trial is an early Phase 1 study, currently recruiting participants in the United States to evaluate the agent's safety and imaging properties.
MK-0947 is being studied in one clinical trial, registered as NCT07348250. This is an open-label, early Phase 1 study titled 'Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease.' The trial is recruiting 22 participants in the United States and includes healthy volunteers.
Yes, MK-0947 is also known as [18F]MK-0947. The [18F] designation indicates that the molecule is labeled with the radioactive isotope fluorine-18, which enables it to be detected by positron emission tomography (PET) imaging. Both names refer to the same investigational compound.